Health News (Reuters)

Trump's drug czar nominee withdraws from consideration

WASHINGTON (Reuters) - President Donald Trump's pick for U.S. drug czar withdrew on Tuesday after it become public that he spearheaded a bill that undercut the government's power to crack down on opioid makers that were flooding the market with the addictive painkillers.

Drugmakers Amneal, Impax to combine in generics push

(Reuters) - Amneal Pharmaceuticals LLC is buying peer Impax Laboratories Inc in an all-stock deal as it looks to add heft to its generics business and gain an edge in a tough drug pricing environment.

New cancer drugs help J&J top profit estimates

(Reuters) - Johnson & Johnson reported a higher-than-expected quarterly profit and raised its full-year forecast as the company gained from strong sales of its new cancer drugs.

Chi-Med, AstraZeneca lung cancer drug shrinks resistant tumors

LONDON (Reuters) - An experimental cancer drug discovered by Hutchison China MediTech has demonstrated promising activity in shrinking tumors in lung cancer patients whose disease had worsened following treatment with approved medicines.

Trump says he could jettison drug czar pick

WASHINGTON (Reuters) - U.S. President Donald Trump said on Monday he would review a report that his nominee for drug czar championed a law that weakened the government's ability to fight the nation's opioid epidemic, and said he could consider jettisoning the pick.

Regeneron-Sanofi drug succeeds mid-stage study

(Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study.

U.S. judge in Texas invalidates Allergan patents on Restasis

(Reuters) - A U.S. judge on Monday invalidated patents on Allergan Plc's dry-eye medicine Restasis on grounds that the patents cover ideas that are obvious, sending shares of the pharmaceutical company down 3.5 percent.

Trump says he will 'look into' drug czar pick following report

WASHINGTON (Reuters) - U.S. President Donald Trump said on Monday that he would "look into" a report that his nomination for drug czar championed a law weakening the Drug Enforcement Administration's capacity to slow the flow of drugs that have fueled the country's opioid epidemic.

Exelixis drug improves overall survival in liver cancer patients

(Reuters) - Exelixis Inc's drug to treat a type of liver cancer improved overall survival in patients in a late-stage study that prompted an independent expert group to recommend no further trial, sending the company's shares soaring 31 percent.

Novo Nordisk diabetes drug works; no heart risk-FDA review

(Reuters) - Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, caused no heart risk, and carried only limited risk of sight problems, a preliminary review by the U.S. Food and Drug Administration concluded on Monday, sending the company's shares up 4 percent.

Pharma and medtech industries prepare for hard Brexit

LONDON (Reuters) - Drugmakers and medical devices companies are drawing up plans to protect supply chains in case Britain crashes out of the European Union without a trade deal, and some small service businesses are already relocating to stay inside the bloc.

Israel targets fashion industry over underweight models

TEL AVIV (Reuters) - Israeli lawmakers want to tighten a ban on the employment of underweight models and on the undeclared digital slimming-down of fashion images, amid concern that the measures are being routinely flouted even as they are adopted abroad.

Pages